Back to search

Article

Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy

2024-02-07

Abstract excerpt

<h4>Background</h4> Directing selective complement activation towards tumor cells is an attractive strategy to promote their elimination. We have generated Complement-activating Multimeric immunotherapeutic compleXes (CoMiX) that selectively stimulate the alternative pathway using Factor H Related protein 4 (FHR4) or the classical complement pathways using triple Fc dimers on HER2-expressing tumor cells. <h4>Meth...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cbf9ea31-f3a2-5eaf-ad69-f5a2a8e00352
DOI
10.1101/2024.02.02.578619
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapyDOI 10.1101/2024.02.02.578619
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.Semantic proximity
Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.Semantic proximity
The complement system as a target in cancer immunotherapySemantic proximity
Complement as a Biological Tool to Control Tumor GrowthSemantic proximity
Design and Evaluation of Eb4Mab-7-mG2a: A Dual-Action Anti-EphB4 Monoclonal Antibody for Targeted Breast Cancer TherapySemantic proximity
Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and TrastuzumabSemantic proximity
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59Semantic proximity
Construction and characterization of chimeric FcγR T cells for universal T cell therapySemantic proximity
Complement-specific antibodies: Designing novel anti-inflammatoriesSemantic proximity
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancerSemantic proximity
A three dimensional human immune-tumor cell model reveals the importance of isotypes in antibody-based immunotherapySemantic proximity
A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor ActivitySemantic proximity
Select a neighboring publication to make it the new centre.